Floatz logo

Selumetinib

Malignant Pancreatic Neoplasm

National Cancer Institute (NCI)Small moleculePhase 2Active
BB
67/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
52/ 100
Competitive Position
95/ 100

Competitive context

314 Active assets in the Malignant Pancreatic Neoplasm cohort.

Asset / SponsorPhaseRating
IMMUNOGLOBULIN G1, ANTI-(HUMANIZED MOUSE MONOCLONAL HR3 .BETA.1 CHAIN ANTI-HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR), DISULFIDE WITH HUMANIZED MOUSE MONOCLONAL HR3 .KAPPA.-CHAIN, DIMER
Chinese PLA General Hospital
Phase 4BBB
Metformin
State University of New York - Downstate Medical Center
Phase 2BBB
FLUOROURACILUM
Jonsson Comprehensive Cancer Center
Phase 4BBB
Irinotecan
Jonsson Comprehensive Cancer Center
Phase 3BB
OXALIPLATIN
Jonsson Comprehensive Cancer Center
Phase 4BB

View all 50 →

Same molecule, other indications

Selumetinib is also rated in:

uveal melanomaDormant
BB
Indicative · Phase 3
65 / 100
View asset →
metastatic neoplasmDormant
BB
Indicative · Phase 3
65 / 100
View asset →
pancreatic adenocarcinomaDormant
BB
Indicative · Phase 2
64 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →